跳至主要内容
临床试验/JPRN-UMIN000008963
JPRN-UMIN000008963已完成2 期

Phase II trial of S-1+oxaliplatin+Cetuximab as first-line treatment in patients with kras-wild type unresectable advanced colorectal cancer - KODK 9 - - KODK 9

Department of Surgery Keio University School of Medicine0 个研究点目标入组 35 人开始时间: 2012年9月25日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
35

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.Severe complications 2.History of severe allergy 3.Peripheral sensory 4.Chickenpox 5.Receiving flucytosine 6.Serious infusion reaction has revealed 7. A case with an acute inflammatory disorder 8. Pregnant or lactating women or women of childbearing potential, and no birth-control 9. Active other malignancies. 10. Brain metastasis 11. Atopic dermatitis 12. Not appropriate for the study at the physician's assessment

研究者

发起方
Department of Surgery Keio University School of Medicine

相似试验